Month: April 2026

Hingham Savings Reports First Quarter 2026 Results

Written by Customer Service on April 17, 2026. Posted in Earnings Releases And Operating Results.

HINGHAM, Mass., April 17, 2026 (GLOBE NEWSWIRE) — HINGHAM INSTITUTION FOR SAVINGS (NASDAQ: HIFS), Hingham, Massachusetts announced earnings for the quarter ended March 31, 2026. Earnings Net income for the quarter ended March 31, 2026 was $2,851,000 or $1.30 per share basic and $1.29 per share diluted, as compared to $7,124,000 or $3.27 per share basic and $3.24 per share diluted for the same period last year. The Bank’s annualized return on average equity for the first quarter of 2026 was 2.33%, and the annualized return on average assets was 0.25%, as compared to 6.46% and 0.64% for the same period in last year. Net income per share (diluted) for the first quarter of 2026 decreased by 60.2% compared to the same period in 2025. Core net income for the quarter ended March 31, 2026, which represents net income excluding the after-tax...

NEXGEL Moves Forward Shareholder Update Call to Discuss Celularity Transaction on April 21st at 4:30 P.M. ET

Written by Customer Service on April 17, 2026. Posted in Public Companies.

LANGHORNE, Pa., April 17, 2026 (GLOBE NEWSWIRE) — NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it is moving up its shareholder update conference call from Thursday, April 23rd to Tuesday, April 21st, 2026, at 4:30 P.M. ET. Shareholder Update Call Details:Date: April 21, 2026Time: 4:30 P.M. ETLive Call: 1-800-267-6316 (U.S. Toll Free) or 1-203-518-9783 (International)Webcast: Events and Presentations About NEXGEL, Inc.NEXGEL is a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications. Based in Langhorne,...

Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026

Written by Customer Service on April 17, 2026. Posted in Public Companies.

Preclinical data show encouraging activity of azenosertib combinations in ADC-resistant TNBC, supporting the potential for pipeline expansion beyond ovarian cancerReal-world data demonstrate Cyclin E1-positive ovarian cancer patients have significantly worse outcomes, independent of CCNE1 gene amplification status, reinforcing the potential for azenosertib to address the unmet need for these patientsSAN DIEGO, April 17, 2026 (GLOBE NEWSWIRE) — Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced data from two posters being presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting, taking place April 17-22,...

Evaxion’s AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial

Written by Customer Service on April 17, 2026. Posted in Public Companies.

New phase 2 data from personalized cancer vaccine EVX-01 demonstrates a record-high rate of vaccine targets triggering a tumor-specific immune response The results reinforce that Evaxion’s pioneering AI platform, AI-Immunology™ accurately identifies and selects the most relevant vaccine targets Data will be presented at the American Association for Cancer Research (AACR) Annual MeetingCOPENHAGEN, Denmark, April 17, 2026 – Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, announces new data demonstrating that AI-Immunology™ identifies and selects the most therapeutically relevant vaccine targets. The data will be presented at the AACR Annual Meeting in San Diego, California, on April 22, 2026. 86% of the vaccine targets...

Surgery Partners, Inc. Announces First Quarter 2026 Earnings Release Date and Conference Call Details

Written by Customer Service on April 17, 2026. Posted in Public Companies.

BRENTWOOD, Tenn., April 17, 2026 (GLOBE NEWSWIRE) — Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”), a leading short-stay surgical facility owner and operator, announced the Company will release its first quarter 2026 results before the market opens on Tuesday, May 5, 2026, to be followed by a conference call at 8:30 a.m. (Eastern Time). You can join the call as follows:Dial in number for live access: 1-877-451-6152 (domestic), 1-201-389-0879 (international) Replay (available 3 hours after the call and available until May 19, 2026): 1-844-512-2921 (domestic), 1-412-317-6671 (international) Passcode for the live call and the replay: 13760194Interested investors and other parties may also listen to a simultaneous webcast of the conference call by logging onto the Investor Relations...

New data demonstrates the unique scalability of Evaxion’s AI-Immunology™ platform in glioblastoma

Written by Customer Service on April 17, 2026. Posted in Public Companies.

Data analysis conducted in collaboration with a leading academic medical center shows that AI‑Immunology™ enables vaccine design also for the deadly brain cancer, glioblastoma Uniquely, the platform can identify a novel source of targets to include in glioblastoma cancer vaccines, potentially enhancing their efficacy Data will be presented at the American Association for Cancer Research (AACR) Annual MeetingCOPENHAGEN, Denmark, April 17, 2026 – Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, announces new data demonstrating the platform’s ability to also potentially develop vaccines for glioblastoma (brain cancer). The data, which will be presented at the AACR Annual Meeting in San Diego, California, on April 22, 2026,...

PRAME-directed Cell Therapy Using Immatics’ TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma

Written by Customer Service on April 17, 2026. Posted in Public Companies.

Individual experimental treatment attempt at Hopp Children’s Cancer Center Heidelberg (KiTZ) and Heidelberg University Hospital (UKHD) using a TCR T-cell therapy engineered with a PRAME-directed TCR provided by Immatics 17-year-old adolescent with bulky, rapidly progressing nephroblastoma and no remaining treatment options achieved deep remission, including marked regression of liver, lung and brain metastases; response ongoing at 6 months of follow-upPRAME is a multi-pediatric cancer target, and findings highlight the therapeutic potential of PRAME TCR T-cell therapy in pediatric patients with solid tumorsData will be presented in a late-breaking poster at the AACR Annual Meeting 2026 by Dr. med. Christian M. Seitz, Group Leader at KiTZHouston, Texas and Tuebingen, Germany, April 17, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics”...

Dime to Release Earnings on April 23, 2026

Written by Customer Service on April 17, 2026. Posted in Public Companies.

HAUPPAUGE, N. Y., April 17, 2026 (GLOBE NEWSWIRE) — Dime (NYSE: DCOM) (the “Company”) today announced that the Company expects to release its earnings for the quarter ended March 31, 2026, before the open of the U.S. equity markets on Thursday, April 23, 2026. The Company will conduct a conference call at 9:00 a.m. (ET) on Thursday, April 23, 2026, during which President and Chief Executive Officer (“CEO”), Stuart Lubow, will discuss the Company’s first quarter financial performance. There will be a question-and-answer period after the CEO remarks. Participants may access the conference call via webcast using this link: Webcast Link Here. To participate via telephone, please register in advance using this Registration Link. Upon registration, all telephone participants will receive a one-time confirmation email detailing...

Toll Brothers Announces Final Luxury Home for Sale at Freestone Station in Marietta, Georgia

Written by Customer Service on April 17, 2026. Posted in Public Companies.

Exclusive enclave in Cobb County offers resort-style amenities and a sought-after location MARIETTA, Ga., April 17, 2026 (GLOBE NEWSWIRE) — Toll Brothers, Inc. (NYSE:TOL), the nation’s leading builder of luxury homes, today announced the final opportunity to purchase a new home at Freestone Station, a serene, luxury home community in Marietta, Georgia. Only one quick move-in home remains available for sale in this sought-after community. The final home for sale, located on Home Site 17, features the Hillside Farmhouse home design with 5 bedrooms, 4 baths, and 3,392 square feet of living space. Scheduled for completion in May 2026, this residence combines elegant architecture with modern finishes to create a truly exceptional living experience. Home shoppers can enjoy the convenience of moving into a brand-new Toll Brothers...

Sun Communities, Inc. Announces Date for First Quarter 2026 Earnings Release and Conference Call

Written by Customer Service on April 17, 2026. Posted in Public Companies.

Southfield, MI, April 17, 2026 (GLOBE NEWSWIRE) — Sun Communities, Inc. (NYSE: SUI) (the “Company”), a real estate investment trust (“REIT”) that owns and operates, or has an interest in, manufactured housing (“MH”) and recreational vehicle (“RV”) communities (collectively, the “properties”), announces it will release first quarter 2026 operating results after the market closes on Monday, April 27, 2026. The Company will host a conference call to discuss these results on Tuesday, April 28, 2026, at 11:00 A.M. ET. To Participate in the Conference Call: Dial at least 5 minutes prior to start time.U.S. and Canada: (877) 407-9039International: (201) 689-8470 The conference call will also be available live on the Company’s website www.suninc.com. Conference Call Replay: U.S. and Canada: (844) 512-2921International:...

Month: April 2026

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals